A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukaemia

Trial Profile

A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukaemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs UCART 19 (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; First in man
  • Acronyms PALL
  • Sponsors Servier
  • Most Recent Events

    • 22 Nov 2016 Interim data from this trial are expected to be announced at a scientific meeting in the first half of 2017, according to a Cellectis S.A. media release.
    • 20 Jun 2016 According to a Cellectis media release, first patient has been treated in this study.
    • 03 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top